Business Context and Reporting Period
Company: Travere Therapeutics, Inc. (TVTX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 10, 2025
Principal Event: Update regarding the FDA review of the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS).
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on regulatory developments and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Update
- Advisory Committee Decision: The FDA informed the Company that an advisory committee is no longer needed for the review of the FILSPARI sNDA for FSGS.
- Review Status: The sNDA remains under FDA review.
- PDUFA Target Action Date: January 13, 2026.
- Product Potential: If approved, FILSPARI would be the first medication indicated for FSGS, a rare kidney disorder.
- Clinical Data Support: The sNDA is supported by the Phase 3 DUPLEX Study and Phase 2 DUET Study, which demonstrated rapid, superior, and sustained reductions in proteinuria compared to maximum labeled dose irbesartan.
- Safety Profile: FILSPARI was well-tolerated with a safety profile comparable to irbesartan, including no drug-induced liver injury or fluid overload.
Guidance, Outlook, and Risks
Outlook: Management anticipates a decision by the PDUFA target date of January 13, 2026. The Company highlights that patients achieving proteinuria remission in the DUPLEX Study had a 67% to 77% lower risk of kidney failure.
Risks and Contingencies:
- Regulatory Risk: No guarantee that the FDA will grant approval for FSGS on the anticipated timeline or at all.
- Financial Risk: Risk of inability to raise additional funding required for development or commercialization.
- Operational Risk: Dependence on contractors for manufacturing and clinical drug supply; challenges in manufacturing scale-up.
- Market Risk: Market acceptance, pricing, reimbursement, and competition from current or future generic therapies.
- Macro Risk: Potential impacts from global economic conditions, tariffs, and changes in government agency staffing or prioritization.
Investor Verification Checklist
- Verify the PDUFA target action date of January 13, 2026, for the FILSPARI FSGS sNDA.
- Confirm the FDA's decision to forego an advisory committee meeting and the implications for the review timeline.
- Review the full clinical data from the DUPLEX and DUET studies regarding proteinuria remission and kidney failure risk reduction.
- Assess the Company's current cash runway and capital requirements in light of the upcoming commercial launch of FILSPARI for IgA nephropathy and potential FSGS approval.
- Monitor for any updates on the commercial launch of FILSPARI for IgA nephropathy, which is already approved by the FDA and EMA.